Floatz logo

Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes

Epstein-Barr Virus Infections

Baylor College of MedicineCell therapyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Epstein-Barr Virus Infections cohort.

Asset / SponsorPhaseRating
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Star0602
Marengo Therapeutics, Inc.
Phase 1/2CCC
Epstein-Barr Virus Specific T-Lymphocytes
Jessie L. Alexander
Phase 1/2CCC

Same molecule, other indications

Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes is also rated in:

Epstein-Barr virus-related tumorDormant
CCC
Indicative ·
52 / 100
View asset →
EBV-associated MalignanciesDormant
CCC
Indicative ·
52 / 100
View asset →
post-transplant lymphoproliferative diseaseDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →